

Lumito AB signs a Letter of Intent with Katana Labs GmbH

Lumito has signed a "Letter of Intent" with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements".

For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in the scanner. Together with Katana Labs' AI-based platform, PAIKON, Lumito's customers gain access to a powerful tool for histopathological analysis of tissue.

Lumito's scanning service allows that the customer prepares its tissue sample with the company's reagent kit, SCIZYS Erbium Kit. The prepared tissue sample is then sent to Lumito for scanning with the SCIZYS scanner. The tissue images are uploaded into Katana Labs' cloud platform, PAIKON, where the customer can visualize the histopathological tissue images and perform advanced image analysis. The service is a way to lower the threshold for future customers and make it easy to evaluate Lumito's product SCIZYS before a major investment.

"We are very pleased to be able to offer Katana Lab's image analysis tool, PAIKON, to our future customers. We have evaluated PAIKON for a year, both internally and externally, where we received very positive feedback about the analysis tool's user-friendliness and see it as an obvious next step to sign a letter of intent to be able to offer our customers to view and analyse their tissue images in a cloud- and AI-based image analysis solution," says Lumito's CEO, Sanna Wallenborg.

"Through this exciting collaboration with Lumito, a pioneer in advanced imaging technology, Katana Labs is set to expand its cloud platform and AI services to a broader market of biomedical researchers. This partnership promises to have a transformative impact on the future of spatial analysis in oncology research", says Katana Labs CEO Falk Zakrzewski.

"We consider Lumito's product SCIZYS and Katana Lab's product PAIKON to be a winning combination and look forward to offering this package to future customers," concludes Sanna Wallenborg.

About Katana Labs

Katana Labs GmbH is revolutionizing cancer research and diagnostics by leveraging the power of AI and the convenience of cloud services. The company's cloud-based platform PAIKON offers advanced tools for processing, visualizing, and AI-powered segmentation of digital histopathology images. This enables pathologists to perform efficient and accurate biomarker analysis for use in clinical diagnostics, biomedical research, and spatial biology.

About Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

Attachments

[Lumito AB signs a Letter of Intent with Katana Labs GmbH](#)